Fig. 1From: Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational studyOutcome analysis. Results of Cox analysis on primary and secondary outcomes. Event rates are reported as number of events/1000 person-yearsBack to article page